Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

INTRODUCTION: About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: León López, Rafael, Fernández, Sheila Cárcel, Limia Pérez, Laura, Romero Palacios, Alberto, Fernández-Roldán, María Concepción, Aguilar Alonso, Eduardo, Pérez Camacho, Inés, Rodriguez-Baño, Jesús, Merchante, Nicolás, Olalla, Julián, Esteban-Moreno, M Ángeles, Santos, Marta, Luque-Pineda, Antonio, Torre-Cisneros, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668373/
https://www.ncbi.nlm.nih.gov/pubmed/33191263
http://dx.doi.org/10.1136/bmjopen-2020-039951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668373/
https://www.ncbi.nlm.nih.gov/pubmed/33191263
http://dx.doi.org/10.1136/bmjopen-2020-039951

Ejemplares similares